- > Media & Investors
- > Media Relations
- > Press Releases
- > Japanese Government to Stockpile Inavir® Anti-influenza Drug for Combatting Pandemic Influenza Threats in Japan
For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Japanese Government to Stockpile Inavir® Anti-influenza Drug for Combatting Pandemic Influenza Threats in Japan
Tokyo, Japan (March 26, 2018) – Daiichi Sankyo Company, Limited (Headquarters, Chuo-ku, Tokyo; hereafter, Daiichi Sankyo) today announced that the purchase of Daiichi Sankyo’s anti-influenza drug, Inavir® Dry Powder Inhaler 20 mg (generic name, laninamivir octanoate hydrate), was announced in the March 22, 2018, issue of the Government Gazette of Japan for stockpiling under the National Action Plan for Pandemic Influenza and New Infectious Diseases of the Japanese government, which compiles prompt and reliable responses to pandemic influenza threats.
1. Summary of Information in Government Gazette (designation and amount of purchase)
Anti-influenza drug (Inavir Dry Powder Inhaler 20 mg): Purchase of an amount sufficient for treating about 3.81 million people
Note: A discretionary contract for this purchase is scheduled to be signed on April 12, 2018.
Inavir, a long-acting neuraminidase inhibitor discovered by Daiichi Sankyo, was launched in October 2010 in Japan, which has the indications of the treatment and prevention of A/B influenza virus infections.